Clinical trial results:
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects with Atopic Dermatitis

Summary

EudraCT number	2021-006902-61
Trial protocol	PL
Global end of trial date	30 September 2022

Results information

Result version number	v1 (current)
This version publication date	08 November 2024
First version publication date	08 November 2024

Trial information

Trial identification

Sponsor protocol code	ARQ-151-311

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT04773587
WHO universal trial number (UTN)	-
Other trial identifiers	IND: 135681

Notes:

Sponsors

Sponsor organisation name	Arcutis Biotherapeutics, Inc.
Sponsor organisation address	3027 Townsgate Rd #300, Westlake Village,, United States, 91361
Public contact	Arcutis Medical Information, Arcutis Biotherapeutics, Inc., +1 (844) 692-6729, information@arcutis.com
Scientific contact	Arcutis Medical Information, Arcutis Biotherapeutics, Inc., +1 (844) 692-6729, information@arcutis.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	30 September 2022
Is this the analysis of the primary completion data?	Yes
Primary completion date	30 September 2022
Global end of trial reached?	Yes
Global end of trial date	30 September 2022
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The goal of this study was to assess the safety and efficacy of ARQ-151 cream vs vehicle applied once a day for 4 weeks by subjects with atopic dermatitis (eczema). This was a parallel group, double blind, vehicle-controlled study in which ARQ-151 cream or vehicle is applied once daily for 4 weeks to subjects with atopic dermatitis.

Protection of trial subjects:

This study was conducted in accordance with the Declaration of Helsinki, ICH Good Clinical Practice, and all applicable local laws/regulations.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	12 January 2021
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Poland: 24
Country: Number of subjects enrolled	Canada: 132
Country: Number of subjects enrolled	United States: 498
Worldwide total number of subjects	654
EEA total number of subjects	24

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	130
Adolescents (12-17 years)	166
Adults (18-64 years)	324
From 65 to 84 years	34

85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

This study was conducted at 65 centers in the United States, Canada, and Poland.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Assessor

Arms

Are arms mutually exclusive?	Yes
Arm title	Roflumilast Cream 0.15%

Arm description:

Participants with mild to moderate AD applied roflumilast cream 0.15% once daily (QD) for 4 weeks.

Arm type	Experimental
Investigational medicinal product name	Roflumilast cream 0.15%
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical

Dosage and administration details:

Applied to affected areas QD for 4 weeks

Arm title	Vehicle Cream

Arm description:

Participants with mild to moderate AD applied vehicle cream QD for 4 weeks.

Arm type	Placebo
Investigational medicinal product name	Vehicle Cream
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Cream
Routes of administration	Topical

Dosage and administration details:

Applied to affected areas QD for 4 weeks.

Number of subjects in period 1	Roflumilast Cream 0.15%	Vehicle Cream
Started	433	221
Completed	404	208
Not completed	29	13
Consent withdrawn by subject	4	5
Consent withdrawn due to AE	1	-

Adverse event, non-fatal	6	3
Lost to follow-up	11	3
Noncompliance	1	-
Lack of efficacy	5	2
Protocol deviation	1	-

Baseline characteristics

Reporting groups	
Reporting group title	Roflumilast Cream 0.15%
Reporting group description:	
Participants with mild to moderate AD applied roflumilast cream 0.15% once daily (QD) for 4 weeks.	
Reporting group title	Vehicle Cream
Reporting group description:	
Participants with mild to moderate AD applied vehicle cream QD for 4 weeks.	

Reporting group values	Roflumilast Cream 0.15%	Vehicle Cream	Total
Number of subjects	433	221	654
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	88	42	130
Adolescents (12-17 years)	112	54	166
Adults (18-64 years)	209	115	324
From 65-84 years	24	10	34
85 years and over	0	0	0
Age continuous Units: years			
arithmetic mean	28.1	28.5	
standard deviation	± 19.14	± 18.94	-
Gender categorical Units: Subjects			
Female	237	129	366
Male	196	92	288
Ethnicity Units: Subjects			
Hispanic or Latino	99	56	155
Not Hispanic or Latino	333	164	497
Unknown or Not reported	1	1	2
Race Units: Subjects			
White	261	129	390
American Indian or Alaska Native	2	0	2
Asian	63	32	95
Native Hawaiian or other Pacific Islander	1	0	1
Black or African American	80	46	126
Multiple	12	6	18
Other	14	8	22
validated Investigator's Global Assessment Scale for Atopic Dermatitis			

(vIGA-AD)			
The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (reported only in integers of 0 to 4 where 0 is clear), with higher scores indicative of greater symptom severity.			
Units: Subjects			
Mild	103	59	162
Moderate	330	162	492

End points

End points reporting groups

Reporting group title	Roflumilast Cream 0.15%
Reporting group description:	
Participants with mild to moderate AD applied roflumilast cream 0.15% once daily (QD) for 4 weeks.	
Reporting group title	Vehicle Cream
Reporting group description:	
Participants with mild to moderate AD applied vehicle cream QD for 4 weeks.	

Primary: Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 4

End point title	Achievement of Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) Success at Week 4
End point description:	
The percentage of participants achieving vIGA-AD "success" is presented with multiple imputation of missing observations. vIGA-AD "success" is defined as a vIGA-AD score of 'clear' or 'almost clear' PLUS a 2-grade improvement from Baseline. The vIGA-AD is astatic evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (reported only in integers of 0 to 4 where 0 is clear),with higher scores indicative of greater symptom severity. All randomized participants are included.	
End point type	Primary
End point timeframe:	
Week 4	

End point values	Roflumilast Cream 0.15%	Vehicle Cream		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	433	221		
Units: percentage of participants				
number (confidence interval 95%)	32.0 (27.79 to 36.63)	15.2 (11.06 to 20.64)		

Statistical analyses

Statistical analysis title	Difference in vIGA-AD Success at Week 4
Comparison groups	Roflumilast Cream 0.15% v Vehicle Cream
Number of subjects included in analysis	654
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [1]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Odds ratio (OR)
Point estimate	2.96

Confidence interval	
level	95 %
sides	2-sided
lower limit	1.881
upper limit	4.647

Notes:

[1] - Stratified by pooled study site and vIGA-AD randomization strata with multiple imputation of missing observations

Secondary: Achievement of vIGA-AD Success at Week 4 in Participants With "Moderate" Baseline Scores

End point title	Achievement of vIGA-AD Success at Week 4 in Participants With "Moderate" Baseline Scores

End point description:

The percentage of participants with moderate baseline scores achieving vIGA-AD "success" is presented with multiple imputation of missing observations. vIGA-AD "success" is defined as a vIGA-AD score of 'clear' or 'almost clear' PLUS a 2-grade improvement from Baseline in participants with a 'moderate' baseline vIGA-AD score. The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (0 'clear' to 4 'severe'), with higher scores indicative of greater symptom severity. All randomized participants who were included in the "moderate" baseline vIGA-AD group during randomization are included.

End point type	Secondary

End point timeframe:

Week 4

End point values	Roflumilast Cream 0.15%	Vehicle Cream		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	328	164		
Units: percentage of participants				
number (confidence interval 95%)	35.0 (29.97 to 40.36)	17.5 (12.38 to 24.13)		

Statistical analyses

Statistical analysis title	Difference in vIGA-AD Success at Week 4
Comparison groups	Vehicle Cream v Roflumilast Cream 0.15%
Number of subjects included in analysis	492
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [2]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Odds ratio (OR)
Point estimate	2.67
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.64
upper limit	4.359

Notes:

[2] - Stratified by pooled study site with multiple imputation of missing observations

Secondary: Achievement of a 4-Point Reduction in the Average, Weekly WI-NRS at Week 4 in Participants ≥12 Years of Age With Baseline WI-NRS ≥ 4

End point title	Achievement of a 4-Point Reduction in the Average, Weekly WI-NRS at Week 4 in Participants ≥12 Years of Age With Baseline WI-NRS ≥ 4

End point description:

The percentage of participants ≥12 years of age with a baseline WI-NRS ≥4 achieving WI-NRS success at Week 4 is presented with multiple imputation of missing observations. The WI-NRS is a simple, single item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the participant experienced in the previous 24 hours (higher scores indicate higher itch severity). All randomized participants ≥12 years of age with a baseline WI-NRS ≥4 are included.

End point type	Secondary

End point timeframe:

Week 4

End point values	Roflumilast Cream 0.15%	Vehicle Cream		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	278	135		
Units: percentage of participants				
number (confidence interval 95%)	33.6 (28.19 to 39.41)	20.7 (14.61 to 28.58)		

Statistical analyses

Statistical analysis title	WI-NRS Success at Week 4
Comparison groups	Roflumilast Cream 0.15% v Vehicle Cream
Number of subjects included in analysis	413
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0089 [3]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Odds ratio (OR)
Point estimate	1.98
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.186
upper limit	3.319

Notes:

[3] - Stratified by pooled study site and vIGA-AD randomization strata with multiple imputation of missing observations

Secondary: Achievement of a 4-Point Reduction in the Average, Weekly WI-NRS at Week 2 in Participants ≥12 Years of Age With Baseline WI-NRS ≥ 4

End point title	Achievement of a 4-Point Reduction in the Average, Weekly WI-NRS at Week 2 in Participants ≥12 Years of Age With Baseline WI-NRS ≥ 4

End point description:

The percentage of participants ≥12 years of age with a baseline WI-NRS ≥4 achieving WI-NRS success at Week 2 is presented with multiple imputation of missing observations. The WI-NRS is a simple, single item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch") to 10 ("worst imaginable itch") the participant experienced in the previous 24 hours (higher scores indicate higher itch severity). All randomized participants ≥12 years of age with a baseline WI-NRS ≥4 are included.

End point type	Secondary

End point timeframe:

Week 2

End point values	Roflumilast Cream 0.15%	Vehicle Cream		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	278	135		
Units: percentage of participants				
number (confidence interval 95%)	23.8 (19.14 to 29.24)	9.8 (5.79 to 16.03)		

Statistical analyses

Statistical analysis title	WI-NRS Success at Week 2
Comparison groups	Vehicle Cream v Roflumilast Cream 0.15%
Number of subjects included in analysis	413
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0016
Method	Cochran-Mantel-Haenszel
Parameter estimate	Odds ratio (OR)
Point estimate	2.81
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.45
upper limit	5.457

Secondary: Achievement of a 4-Point Reduction in the Average, Weekly WI-NRS at Week 1 in Participants ≥12 Years of Age With Baseline WI-NRS ≥ 4

End point title	Achievement of a 4-Point Reduction in the Average, Weekly WI-NRS at Week 1 in Participants ≥12 Years of Age With Baseline WI-NRS ≥ 4

End point description:

The percentage of participants ≥12 years of age with a baseline WI-NRS ≥4 achieving WI-NRS success at Week 1 is presented with multiple imputation of missing observations. The WI-NRS is a simple, single item scale to assess the subject-reported severity of this symptom, on a scale ranging from 0 ("no itch")

to 10 ("worst imaginable itch") the participant experienced in the previous 24 hours (higher scores indicate higher itch severity). All randomized participants ≥12 years of age with a baseline WI-NRS ≥4 are included.

End point type	Secondary

End point timeframe:

Week 1

End point values	Roflumilast Cream 0.15%	Vehicle Cream		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	278	135		
Units: percentage of participants				
number (confidence interval 95%)	9.5 (6.60 to 13.60)	2.3 (0.77 to 6.41)		

Statistical analyses

Statistical analysis title	WI-NRS Success at Week 1
Comparison groups	Vehicle Cream v Roflumilast Cream 0.15%
Number of subjects included in analysis	413
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0159 [4]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Odds ratio (OR)
Point estimate	3.81
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.161
upper limit	12.511

Notes:

[4] - Stratified by pooled study site and vIGA-AD randomization strata with multiple imputation of missing observations

Secondary: Achievement of ≥ 75% Reduction in the Eczema Area and Severity Index (EASI-75) at Week 4

End point title	Achievement of ≥ 75% Reduction in the Eczema Area and Severity Index (EASI-75) at Week 4

End point description:

The percentage of participants achieving EASI-75 is presented with multiple imputation of missing observations. EASI-75 is a ≥75% reduction from the baseline EASI score. EASI combines the assessment of the severity of lesions and the area affected into a single total score in the range 0 (no disease) to 72 (maximal disease). To calculate the EASI, the sum of the severity rating (0 to 3 with 3 being the most severe) for four clinical signs are multiplied with the numerical value of the area affected and with the percentage of the four body areas. All randomized participants are included.

End point type	Secondary

End point timeframe:

Week 4

End point values	Roflumilast Cream 0.15%	Vehicle Cream		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	433	221		
Units: percentage of participants				
number (confidence interval 95%)	43.2 (38.54 to 47.94)	22.0 (16.97 to 28.04)		

Statistical analyses

Statistical analysis title	EASI-75 at Week 4
Comparison groups	Vehicle Cream v Roflumilast Cream 0.15%
Number of subjects included in analysis	654
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [5]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Odds ratio (OR)
Point estimate	3.17
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.102
upper limit	4.795

Notes:

[5] - Stratified by pooled study site and vIGA-AD randomization strata with multiple imputation of missing observations

Secondary: Achievement of vIGA-AD Score of ‘Clear’ or ‘Almost Clear’ at Week 4

End point title	Achievement of vIGA-AD Score of ‘Clear’ or ‘Almost Clear’ at Week 4

End point description:

The percentage of participants scoring 'clear' or 'almost clear' on vIGA-AD at Week 4 is presented with multiple imputation of missing observations. The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (0 'clear' to 4 'severe'), with higher scores indicative of greater symptom severity. All randomized participants are included.

End point type	Secondary

End point timeframe:

Week 4

End point values	Roflumilast Cream 0.15%	Vehicle Cream		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	433	221		
Units: percentage of participants				
number (confidence interval 95%)	41.5 (36.93 to 46.25)	25.2 (19.91 to 31.41)		

Statistical analyses

Statistical analysis title	vIGA-AD 'Clear' or 'Almost Clear' at Week 4
Comparison groups	Roflumilast Cream 0.15% v Vehicle Cream
Number of subjects included in analysis	654
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [6]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Odds ratio (OR)
Point estimate	2.56
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.707
upper limit	3.843

Notes:

[6] - Stratified by pooled study site and vIGA-AD randomization strata with multiple imputation of missing observations

Secondary: Achievement of vIGA-AD Success at Week 2

End point title	Achievement of vIGA-AD Success at Week 2

End point description:

The percentage of participants achieving "success" on the VIGA-AD at Week 2 is presented with multiple imputation of missing observations. vIGA-AD "success" is defined as a vIGA-AD score of 'clear' or 'almost clear' PLUS a 2-grade improvement from Baseline. The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (0 'clear' to 4 'severe'), with higher scores indicative of greater symptom severity. All randomized participants are included.

End point type	Secondary

End point timeframe:

Week 2

End point values	Roflumilast Cream 0.15%	Vehicle Cream		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	433	221		
Units: percentage of participants				
number (confidence interval 95%)	21.2 (17.57 to 25.33)	6.4 (3.84 to 10.44)		

Statistical analyses

Statistical analysis title	vIGA-AD Success at Week 2
Comparison groups	Vehicle Cream v Roflumilast Cream 0.15%
Number of subjects included in analysis	654
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001
Method	Cochran-Mantel-Haenszel
Parameter estimate	Odds ratio (OR)
Point estimate	4.28
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.31
upper limit	7.926

Secondary: Achievement of vIGA-AD Success at Week 1

End point title	Achievement of vIGA-AD Success at Week 1

End point description:

The percentage of participants achieving "success" on the VIGA-AD at Week 1 is presented with multiple imputation of missing observations. vIGA-AD "success" is defined as a vIGA-AD score of 'clear' or 'almost clear' PLUS a 2-grade improvement from Baseline. The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (0 'clear' to 4 'severe'), with higher scores indicative of greater symptom severity. All randomized participants are included.

End point type	Secondary

End point timeframe:

Week 1

End point values	Roflumilast Cream 0.15%	Vehicle Cream		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	433	221		
Units: percentage of participants				
number (confidence interval 95%)	8.1 (5.87 to 11.03)	0.5 (0.08 to 2.52)		

Statistical analyses

Statistical analysis title	vIGA-AD Success at Week 1
Comparison groups	Roflumilast Cream 0.15% v Vehicle Cream
Number of subjects included in analysis	654
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [7]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Odds ratio (OR)
Point estimate	25.41
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.815
upper limit	229.388

Notes:

[7] - Stratified by pooled study site and vIGA-AD randomization strata with multiple imputation of missing observations

Secondary: Achievement of vIGA-AD Score of 'Clear' or 'Almost Clear' at Week 2

End point title	Achievement of vIGA-AD Score of 'Clear' or 'Almost Clear' at Week 2

End point description:

The percentage of participants scoring 'clear' or 'almost clear' on vIGA-AD at Week 2 is presented with multiple imputation of missing observations. The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (0 'clear' to 4 'severe'), with higher scores indicative of greater symptom severity. All randomized participants are included.

End point type	Secondary

End point timeframe:

Week 2

End point values	Roflumilast Cream 0.15%	Vehicle Cream		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	433	221		
Units: percentage of participants				
number (confidence interval 95%)	31.8 (27.58 to 36.38)	13.6 (9.72 to 18.79)		

Statistical analyses

Statistical analysis title	vIGA-AD 'Clear' or 'Almost Clear' at Week 2
Comparison groups	Roflumilast Cream 0.15% v Vehicle Cream

Number of subjects included in analysis	654
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 [8]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Odds ratio (OR)
Point estimate	3.62
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.217
upper limit	5.911

Notes:

[8] - Stratified by pooled study site and vIGA-AD randomization strata with multiple imputation of missing observations

Secondary: Achievement of vIGA-AD Score of 'Clear' or 'Almost Clear' at Week 1

End point title	Achievement of vIGA-AD Score of 'Clear' or 'Almost Clear' at Week 1

End point description:

The percentage of participants scoring 'clear' or 'almost clear' on vIGA-AD at Week 1 is presented with multiple imputation of missing observations. The vIGA-AD is a static evaluation of qualitative overall AD severity. This global assessment scale is an ordinal scale with five severity grades (0 'clear' to 4 'severe'), with higher scores indicative of greater symptom severity. All randomized participants are included.

End point type	Secondary

End point timeframe:

Week 1

End point values	Roflumilast Cream 0.15%	Vehicle Cream		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	433	221		
Units: percentage of participants				
number (confidence interval 95%)	14.3 (11.33 to 17.93)	5.9 (3.47 to 9.80)		

Statistical analyses

Statistical analysis title	vIGA-AD 'Clear' or 'Almost Clear' at Week 1
Comparison groups	Vehicle Cream v Roflumilast Cream 0.15%
Number of subjects included in analysis	654
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0002 [9]
Method	Cochran-Mantel-Haenszel
Parameter estimate	Odds ratio (OR)
Point estimate	3.46

Confidence interval	
level	95 %
sides	2-sided
lower limit	1.705
upper limit	7.007

Notes:

[9] - Stratified by pooled study site and vIGA-AD randomization strata with multiple imputation of missing observations

Adverse events

Adverse events information[1]	
Timeframe for reporting adverse events:	
Up to approximately 29 days	
Assessment type	Systematic

Dictionary used	
Dictionary name	MedDRA
Dictionary version	25.0

Reporting groups	
Reporting group title	Roflumilast Cream 0.15%
Reporting group description:	
Participants with mild to moderate AD applied roflumilast cream 0.15% QD for 4weeks.	
Reporting group title	Vehicle Cream
Reporting group description:	
Participants with mild to moderate AD applied vehicle cream QD for 4 weeks.	

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.
Justification: There were no nonserious adverse events meeting the cutoff threshold.

Serious adverse events	Roflumilast Cream 0.15%	Vehicle Cream	
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 433 (0.92%)	0 / 221 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events			
Vascular disorders			
Pulmonary embolism			
subjects affected / exposed	1 / 433 (0.23%)	0 / 221 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Psychiatric disorders			
Depression			
subjects affected / exposed	1 / 433 (0.23%)	0 / 221 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Suicidal ideation			
subjects affected / exposed	1 / 433 (0.23%)	0 / 221 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			

Diverticulitis			
subjects affected / exposed	1 / 433 (0.23%)	0 / 221 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Roflumilast Cream 0.15%	Vehicle Cream	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 433 (0.00%)	0 / 221 (0.00%)	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported